DFX Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.
Borrower
N••••••
Pharmaceuticalsgroup grade Bon a schedule nowsponsor unattributed
Also written as: 01; 16; LLC Date 07; LLC Date 07/01/16
What matters now
- 99¢ → 100¢consensus mark
Consensus mark 100¢ on cost, up from 99¢ a year ago, 98¢ last quarter.
Q1 2026 · The lenders' own valuations moved back up.
Derived1 of 1 lender' own marks, weighted by principal - $27.6Mprincipal outstanding
$27.6M principal held by 1 lender; matures Nov 2026.
Q1 2026 · Refinancing is due in 1 months at a 100¢ mark.
FactBDC schedules of investments, 31 Mar 2026; a sum of the BDCs' pieces, a lower bound
Mark path, consensus per quarter end
99¢ · 98¢ · 98¢ · 98¢ · 100¢Q1 2025 to Q1 2026
Principal held
at least $27.6M
sum of BDC pieces, a lower bound
Fair value
$27.6M
100c on cost, debt pieces
Unfunded
Not disclosed
commitments not yet drawn
BDC lenders
1
1 on the latest quarter
Facilities
1
0 equity pieces beside them
Next maturity
Nov 1, 2026
$27.6M inside 24 months
On the tape since
Dec 31, 2022
latest Mar 31, 2026
Events
4
dated, non-routine
Lender marks
each lender's own fair value over cost at Mar 31, 2026, folded to one row per lender
| Lender | Exposure | Current mark | QoQ change |
|---|---|---|---|
| T•• D••••• L•••••• L•• | $27.6M | 100¢ | +2 pts |
Every BDC piece · 1 position across 1 lenderlargest principal first, with instrument and rate
| BDC | Instrument | Principal | Fair value | Rate |
|---|---|---|---|---|
| T•• D••••• L•••••• L•• | term loan lien unstated T••• L••• – 12.19% inc PIK (S••• + 8.38%, 1.00% F••••, 0.38% PIK) Net Assets 12.7% M•••••• | $27.6M | $27.6M 100c | SOFR+838 bp PIK 0.38% |
Capital structure as the BDCs see it
latest quarter end Mar 31, 2026
| Facility | Held | On cost | Pricing | Maturity | BDCs |
|---|---|---|---|---|---|
| term loan lien unstated exited Mar 31, 2026 | at least $27.6M | 100c | SOFR+838 bp PIK 0.38% | Nov 1, 2026 | 1 |
Through time
the borrower's pieces summed across BDCs, every quarter end
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Mar 31, 2026 | 1 | $27.6M | $27.6M | 100c | 1 |
| Dec 31, 2025 | 1 | $27.6M | $27.1M | 98c | 1 |
| Sep 30, 2025 | 1 | $27.6M | $27.0M | 98c | 1 |
| Jun 30, 2025 | 1 | $27.6M | $27.1M | 98c | 1 |
All 14 quartersShow fewer
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Mar 31, 2025 | 1 | $28.0M | $27.8M | 99c | 1 |
| Dec 31, 2024 | 1 | $56.0M | $55.3M | 99c | 2 |
| Sep 30, 2024 | 1 | $44.0M | $43.1M | 98c | 1 |
| Jun 30, 2024 | 1 | $43.9M | $43.0M | 98c | 1 |
| Mar 31, 2024 | 1 | $43.9M | $43.0M | 98c | 1 |
| Dec 31, 2023 | 1 | $43.9M | $43.5M | 99c | 1 |
| Sep 30, 2023 | 1 | $43.9M | $43.1M | 98c | 1 |
| Jun 30, 2023 | 1 | $44.1M | $42.9M | 97c | 1 |
| Mar 31, 2023 | 1 | $44.1M | $43.0M | 98c | 1 |
| Dec 31, 2022 | 1 | $88.2M | $87.3M | 99c | 2 |
What changed
- Facility left every BDC scheduleMar 31, 2026
- Maturity extended (observed)Mar 31, 2026
- Maturity extended (observed)Mar 31, 2026
- Maturity extended (observed)Mar 31, 2024
- Maturity extended (observed)Mar 31, 2024
Full timeline · 7 eventsShow fewer
- Maturity extended (observed)Mar 31, 2023
- Maturity extended (observed)Mar 31, 2023
Sponsor
No sponsor attribution: no portfolio page, deal announcement or Form D signer consensus names an owner for this borrower group.
Identity
- Group key
- NORAMCOderivedthe codename stem after legal suffixes and deal words
- Spellings
- 1 across 1 BDCderived
- Industry
- Pharmaceuticalsreportedas one filer wrote it